Overview

A Phase I Study of QL1604 for Advanced Solid Tumors

Status:
Active, not recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.